Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Levosimendan · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| levosimendan | DRUG | - |
| dobutamine | DRUG | - |
Inclusion Criteria: * Written, signed and dated informed consent * Male and female patients over 18 years of age. Females of childbearing potential must have a negative pregnancy test and must refrain from breastfeeding. Women who are postmenopausal \[two years since last menstrual cycle\], surgica...
Levosimendan is an investigational small molecule being developed for the treatment of heart failure, specifically congestive heart failure and acute heart failure. It is administered intravenously and is intended for patients with decompensated chronic heart failure or acute heart failure in need of inotropic support.
Levosimendan is being developed by Abbott Laboratories, a company publicly traded under the ticker symbol ABT. The drug is currently in Phase 3 clinical development for cardiovascular indications.
Levosimendan is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed, but the drug remains under investigation for the treatment of heart failure.
Levosimendan has been studied in two completed Phase 3 trials. NCT00048425 evaluated its efficacy in decompensated chronic heart failure with 600 participants. NCT00348504 compared Levosimendan to dobutamine in 1300 patients with acute heart failure. Both trials were randomized and double-blind.
No, Levosimendan is not the same as dobutamine. Levosimendan is an investigational drug being developed by Abbott Laboratories, while dobutamine is a separate, established inotropic agent. The two were compared head-to-head in a clinical trial for acute heart failure.